Weidong Hu

3.0k total citations · 1 hit paper
44 papers, 1.9k citations indexed

About

Weidong Hu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Weidong Hu has authored 44 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Molecular Biology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Weidong Hu's work include Lung Cancer Treatments and Mutations (8 papers), Ferroptosis and cancer prognosis (7 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Weidong Hu is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Ferroptosis and cancer prognosis (7 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Weidong Hu collaborates with scholars based in China, United States and Vietnam. Weidong Hu's co-authors include Sufang Tian, Haibo Xu, Li Niu, Huan Liu, Shu‐Yuan Xiao, Wenhui Zhou, Lu Lv, Sheng Li, Yujin Wang and Congkuan Song and has published in prestigious journals such as PLoS ONE, Cancer and Journal of Cellular Physiology.

In The Last Decade

Weidong Hu

43 papers receiving 1.8k citations

Hit Papers

Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus... 2020 2026 2022 2024 2020 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weidong Hu China 17 723 538 472 451 360 44 1.9k
Ying-Nan Wang China 6 866 1.2× 464 0.9× 223 0.5× 505 1.1× 447 1.2× 6 1.8k
Furong Zeng China 22 538 0.7× 672 1.2× 532 1.1× 359 0.8× 412 1.1× 69 1.9k
Guangtong Deng China 22 532 0.7× 607 1.1× 541 1.1× 357 0.8× 364 1.0× 67 1.8k
Jiong Yu China 24 837 1.2× 618 1.1× 215 0.5× 278 0.6× 242 0.7× 76 2.2k
Yan Ding China 18 447 0.6× 409 0.8× 126 0.3× 273 0.6× 193 0.5× 58 1.4k
Jing Yu China 20 315 0.4× 501 0.9× 363 0.8× 883 2.0× 257 0.7× 61 1.7k
Da Xu China 24 300 0.4× 839 1.6× 401 0.8× 609 1.4× 592 1.6× 71 2.1k
Sufang Tian China 12 1.3k 1.7× 228 0.4× 380 0.8× 357 0.8× 66 0.2× 41 2.0k
Jing Cao China 20 318 0.4× 516 1.0× 140 0.3× 221 0.5× 339 0.9× 67 1.2k

Countries citing papers authored by Weidong Hu

Since Specialization
Citations

This map shows the geographic impact of Weidong Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weidong Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weidong Hu more than expected).

Fields of papers citing papers by Weidong Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weidong Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weidong Hu. The network helps show where Weidong Hu may publish in the future.

Co-authorship network of co-authors of Weidong Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Weidong Hu. A scholar is included among the top collaborators of Weidong Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weidong Hu. Weidong Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Dong, Daoquan Liu, Xianguo Wang, et al.. (2024). Advantages of robot-assisted resection of large mediastinal tumors: a single-center preliminary study. Journal of Robotic Surgery. 18(1). 190–190. 1 indexed citations
2.
Li, Binghui, Muyang Yang, Lisen Lu, et al.. (2024). Irradiated microparticles suppress prostate cancer by tumor microenvironment reprogramming and ferroptosis. Journal of Nanobiotechnology. 22(1). 225–225. 19 indexed citations
3.
Wang, Yujin, Qingwen Wang, Donghu Yu, et al.. (2021). Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation. Journal of Cancer Research and Clinical Oncology. 147(11). 3245–3254. 2 indexed citations
4.
Song, Congkuan, Zhi-Quan Wu, Qingwen Wang, et al.. (2021). A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology. 9. 634697–634697. 12 indexed citations
5.
Hu, Weidong, et al.. (2021). Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 65(2). 172–177. 3 indexed citations
7.
Ruan, Xiaolan, Xiaoping Liu, Haoli Ma, et al.. (2020). Analysis of the Interaction Network of Hub miRNAs-Hub Genes, Being Involved in Idiopathic Pulmonary Fibers and Its Emerging Role in Non-small Cell Lung Cancer. Frontiers in Genetics. 11. 302–302. 34 indexed citations
8.
Song, Congkuan, Zixin Guo, Xiaoyan Shen, et al.. (2020). Prognostic Factors Analysis and Nomogram Construction of Dual Primary Lung Cancer: A Population Study. BioMed Research International. 2020(1). 7206591–7206591. 7 indexed citations
9.
Song, Congkuan, Zixin Guo, Donghu Yu, et al.. (2020). A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma. Frontiers in Oncology. 10. 1300–1300. 64 indexed citations
10.
Tian, Sufang, Weidong Hu, Li Niu, et al.. (2020). Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. Journal of Thoracic Oncology. 15(5). 700–704. 989 indexed citations breakdown →
11.
Huang, Jingyu, Aifen Wang, Ganjun Kang, Dejia Li, & Weidong Hu. (2020). Clinical course of patients infected with severe acute respiratory syndrome coronavirus 2 soon after thoracoscopic lung surgery. Journal of Thoracic and Cardiovascular Surgery. 160(2). e91–e93. 6 indexed citations
12.
Wang, Yujin, Weidong Hu, Sheng Li, et al.. (2019). Clinical epidemiological analysis of 2 403 cases of lung cancer.. 46(8). 460–465. 1 indexed citations
13.
Yu, Donghu, Jingyu Huang, Xiaoping Liu, et al.. (2019). Effects of hub genes on the clinicopathological and prognostic features of lung adenocarcinoma. Oncology Letters. 19(2). 1203–1214. 17 indexed citations
14.
Sun, Cheng‐Cao, Qun Zhou, Wei Hu, et al.. (2018). Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging. 10(5). 973–987. 67 indexed citations
15.
Lv, Lu, et al.. (2017). Association between CXCL16/CXCR6 expression and the clinicopathological features of patients with non-small cell lung cancer. Oncology Letters. 13(6). 4661–4668. 16 indexed citations
16.
Tu, Zhenbo, Songping Xie, Meng Xiong, et al.. (2016). CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer. International Journal of Oncology. 50(2). 505–514. 32 indexed citations
17.
Zhou, Wenhui, et al.. (2015). Co-expression of CXCR4 and CXCR7 in human endometrial stromal cells is modulated by steroid hormones.. PubMed. 8(3). 2449–60. 21 indexed citations
19.
Hu, Weidong, et al.. (2014). CXCL16 and CXCR6 Are Coexpressed in Human Lung Cancer In Vivo and Mediate the Invasion of Lung Cancer Cell Lines In Vitro. PLoS ONE. 9(6). e99056–e99056. 47 indexed citations
20.
Hu, Weidong, et al.. (2008). CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Science. 99(7). 1362–1369. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026